NCT04686175View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 21, 2021

Primary Completion Date

October 29, 2024

Study Completion Date

December 13, 2024

Conditions
Ectonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of Infancy
Interventions
DRUG

INZ-701

INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Trial Locations (7)

14050

Parexel International GmbH, Berlin

22529

University of Hamburg (Universitatklinikum Hamburg-Eppendorf), Hamburg

55905

Mayo Clinic, Rochester

75015

Necker University Hospital-Sick Children, Paris

07724

Clinilabs Drug Development Corporation, Eatontown

S7N 0W8

University of Saskatchewan, Saskatoon

SE1 1YR

Richmond Pharmacology (RPL), London

Sponsors

Lead Sponsor

Inozyme Pharma
All Listed Sponsors
lead

Inozyme Pharma

INDUSTRY